Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Uchiyama-Kokubu, N; Watanabe, T; Cohen, D
   Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15
   JAPANESE JOURNAL OF CANCER RESEARCH
   
   N. Uchiyama-Kokubu et al., "Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15", JPN J CANC, 92(10), 2001, pp. 1116-1126
2. Rux, JJ; Burnett, RM
   Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon
   MOLECULAR THERAPY
   
   J.J. Rux e R.M. Burnett, "Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon", MOL THER, 1(1), 2000, pp. 18-30
3. Manzotti, C; Pratesi, G; Menta, E; Di Domenico, R; Cavalletti, E; Fiebig, HH; Kelland, LR; Farrell, N; Polizzi, D; Supino, R; Pezzoni, G; Zunino, F
   BBR 3464: A novel triplatinum complex, exhibiting a preclinical profile ofantitumor efficacy different from cisplatin
   CLINICAL CANCER RESEARCH
   
   C. Manzotti et al., "BBR 3464: A novel triplatinum complex, exhibiting a preclinical profile ofantitumor efficacy different from cisplatin", CLIN CANC R, 6(7), 2000, pp. 2626-2634
4. Stallwood, Y; Fisher, KD; Gallimore, PH; Mautner, V
   Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients
   GENE THERAPY
   
   Y. Stallwood et al., "Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients", GENE THER, 7(8), 2000, pp. 637-643
5. Holford, J; Beale, PJ; Boxall, FE; Sharp, SY; Kelland, LR
   Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines
   EUROPEAN JOURNAL OF CANCER
   
   J. Holford et al., "Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines", EUR J CANC, 36(15), 2000, pp. 1984-1990
6. Berman, DA
   Balanced and purposeful departures: Fixing a jurisprudence that underminesthe federal sentencing guidelines
   NOTRE DAME LAW REVIEW
   
   D.A. Berman, "Balanced and purposeful departures: Fixing a jurisprudence that underminesthe federal sentencing guidelines", NOTRE DAME, 76(1), 2000, pp. 21-108
7. Tidefelt, U; Liliemark, J; Gruber, A; Liliemark, E; Sundman-Engberg, B; Juliusson, G; Stenke, L; Elmhorn-Rosenborg, A; Mollgard, L; Lehman, S; Xu, D; Covelli, A; Gustavsson, B; Paul, C
   P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with p-glycoprotein-positive acute myeloid leukemia
   JOURNAL OF CLINICAL ONCOLOGY
   
   U. Tidefelt et al., "P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with p-glycoprotein-positive acute myeloid leukemia", J CL ONCOL, 18(9), 2000, pp. 1837-1844
8. Merlin, JL; Bour-Dill, C; Marchal, S; Ramacci, C; Poullain, MG; Giroux, B
   Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in golgi vesicles
   CYTOMETRY
   
   J.L. Merlin et al., "Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in golgi vesicles", CYTOMETRY, 41(1), 2000, pp. 62-72
9. Fukushima, T; Yamashita, T; Takemura, H; Suto, H; Kishi, S; Urasaki, Y; Ueda, T
   Effect of PSC 833 on the cytotoxicity and pharmacodynamics of mitoxantronein multidrug-resistant K562 cells
   LEUKEMIA RESEARCH
   
   T. Fukushima et al., "Effect of PSC 833 on the cytotoxicity and pharmacodynamics of mitoxantronein multidrug-resistant K562 cells", LEUK RES, 24(3), 2000, pp. 249-254
10. Eisner, T; Eisner, M
    Defensive use of a fecal thatch by a beetle larva (Hemisphaerota cyanea)
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    
    T. Eisner e M. Eisner, "Defensive use of a fecal thatch by a beetle larva (Hemisphaerota cyanea)", P NAS US, 97(6), 2000, pp. 2632-2636
11. Beale, PJ; Rogers, P; Boxall, F; Sharp, SY; Kelland, LR
    BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
    BRITISH JOURNAL OF CANCER
    
    P.J. Beale et al., "BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma", BR J CANC, 82(2), 2000, pp. 436-440
12. Kelland, LR; Sharp, SY; O'Neill, CF; Raynaud, FI; Beale, PJ; Judson, IR
    Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance
    JOURNAL OF INORGANIC BIOCHEMISTRY
    
    L.R. Kelland et al., "Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance", J INORG BIO, 77(1-2), 1999, pp. 111-115
13. Roovers, DJ; van Vliet, M; Bloem, AC; Lokhorst, HM
    Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines
    LEUKEMIA RESEARCH
    
    D.J. Roovers et al., "Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines", LEUK RES, 23(6), 1999, pp. 539-548
14. Schwartz, DR; Homanics, GE; Hoyt, DG; Klein, E; Abernethy, J; Lazo, JS
    The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    
    D.R. Schwartz et al., "The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance", P NAS US, 96(8), 1999, pp. 4680-4685
15. Lowe, G; Droz, AS; Vilaivan, T; Weaver, GW; Park, JJ; Pratt, JM; Tweedale, L; Kelland, LR
    Cytotoxicity of 2,2 ': 6 ',2 ''-terpyridineplatinum(II) complexes against human ovarian carcinoma
    JOURNAL OF MEDICINAL CHEMISTRY
    
    G. Lowe et al., "Cytotoxicity of 2,2 ': 6 ',2 ''-terpyridineplatinum(II) complexes against human ovarian carcinoma", J MED CHEM, 42(16), 1999, pp. 3167-3174
16. Berger, D; Citarella, R; Dutia, M; Greenberger, L; Hallett, W; Paul, R; Powell, D
    Novel multidrug resistance reversal agents
    JOURNAL OF MEDICINAL CHEMISTRY
    
    D. Berger et al., "Novel multidrug resistance reversal agents", J MED CHEM, 42(12), 1999, pp. 2145-2161
17. Mistry, P; Plumb, J; Eccles, S; Watson, S; Dale, I; Ryder, H; Box, G; Charlton, P; Templeton, D; Bevan, PB
    In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance
    BRITISH JOURNAL OF CANCER
    
    P. Mistry et al., "In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance", BR J CANC, 79(11-12), 1999, pp. 1672-1678
18. Tanabe, H; Tasaka, S; Ohmori, H; Gomi, N; Sasaki, Y; Machida, T; Iino, M; Kiue, A; Naito, S; Kuwano, M
    Newly synthesized dihydropyridine derivatives as modulators of P-glycoprotein-mediated multidrug resistance
    BIOORGANIC & MEDICINAL CHEMISTRY
    
    H. Tanabe et al., "Newly synthesized dihydropyridine derivatives as modulators of P-glycoprotein-mediated multidrug resistance", BIO MED CH, 6(11), 1998, pp. 2219-2227
19. DUFFY CP; ELLIOTT CJ; OCONNOR RA; HEENAN MM; COYLE S; CLEARY IM; KAVANAGH K; VERHAEGEN S; OLOUGHLIN CM; NICAMHLAOIBH R; CLYNES M
    ENHANCEMENT OF CHEMOTHERAPEUTIC DRUG TOXICITY TO HUMAN TUMOR-CELLS IN-VITRO BY A SUBSET OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS)
    European journal of cancer
    
    C.P. Duffy et al., "ENHANCEMENT OF CHEMOTHERAPEUTIC DRUG TOXICITY TO HUMAN TUMOR-CELLS IN-VITRO BY A SUBSET OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS)", European journal of cancer, 34(8), 1998, pp. 1250-1259
20. BERTOUNESQUE E; MILLAL F; MERESSE P; MONNERET C
    SYNTHESIS OF A HIGHLY FUNCTIONALIZED GAMMA-LACTONE AS A PRECURSOR OF 9-PENTYL ANTHRACYCLINES
    Tetrahedron : asymmetry
    
    E. Bertounesque et al., "SYNTHESIS OF A HIGHLY FUNCTIONALIZED GAMMA-LACTONE AS A PRECURSOR OF 9-PENTYL ANTHRACYCLINES", Tetrahedron : asymmetry, 9(17), 1998, pp. 2999-3009
21. PEREGO P; ROMANELLI S; CARENINI N; MAGNANI I; LEONE R; BONETTI A; PAOLICCHI A; ZUNINO F
    OVARIAN-CANCER CISPLATIN-RESISTANT CELL-LINES - MULTIPLE CHANGES INCLUDING COLLATERAL SENSITIVITY TO TAXOL
    Annals of oncology
    
    P. Perego et al., "OVARIAN-CANCER CISPLATIN-RESISTANT CELL-LINES - MULTIPLE CHANGES INCLUDING COLLATERAL SENSITIVITY TO TAXOL", Annals of oncology, 9(4), 1998, pp. 423-430
22. FENART L; BUEESCHERRER V; DESCAMPS L; DUHEM C; POULLAIN MG; CECCHELLI R; DEHOUCK MP
    INHIBITION OF P-GLYCOPROTEIN - RAPID ASSESSMENT OF ITS IMPLICATION INBLOOD-BRAIN-BARRIER INTEGRITY AND DRUG TRANSPORT TO THE BRAIN BY AN IN-VITRO MODEL OF THE BLOOD-BRAIN-BARRIER
    Pharmaceutical research
    
    L. Fenart et al., "INHIBITION OF P-GLYCOPROTEIN - RAPID ASSESSMENT OF ITS IMPLICATION INBLOOD-BRAIN-BARRIER INTEGRITY AND DRUG TRANSPORT TO THE BRAIN BY AN IN-VITRO MODEL OF THE BLOOD-BRAIN-BARRIER", Pharmaceutical research, 15(7), 1998, pp. 993-1000
23. HOLFORD J; RAYNAUD F; MURRER BA; GRIMALDI K; HARTLEY JA; ABRAMS M; KELLAND LR
    CHEMICAL, BIOCHEMICAL AND PHARMACOLOGICAL ACTIVITY OF THE NOVEL STERICALLY HINDERED PLATINUM COORDINATION COMPLEX, CIS-[AMMINEDICHLORO(2-METHYLPYRIDINE)] PLATINUM(II) (AMD473)
    Anti-cancer drug design
    
    J. Holford et al., "CHEMICAL, BIOCHEMICAL AND PHARMACOLOGICAL ACTIVITY OF THE NOVEL STERICALLY HINDERED PLATINUM COORDINATION COMPLEX, CIS-[AMMINEDICHLORO(2-METHYLPYRIDINE)] PLATINUM(II) (AMD473)", Anti-cancer drug design, 13(1), 1998, pp. 1-18
24. FERNANDEZ M; HEREDIA ML; DELACUESTA E; AVENDANO C
    VILSMEIER AND MANNICH REACTIONS ON (4S)-N-2-SUBSTITUTED 4-DIHYDRO-1H-PYRAZINO[2,1-B]QUINAZOLINE-3,6-DIONES
    Tetrahedron
    
    M. Fernandez et al., "VILSMEIER AND MANNICH REACTIONS ON (4S)-N-2-SUBSTITUTED 4-DIHYDRO-1H-PYRAZINO[2,1-B]QUINAZOLINE-3,6-DIONES", Tetrahedron, 54(12), 1998, pp. 2777-2784
25. GALL JGD; CRYSTAL RG; FALCKPEDERSEN E
    CONSTRUCTION AND CHARACTERIZATION OF HEXON-CHIMERIC ADENOVIRUSES - SPECIFICATION OF ADENOVIRUS SEROTYPE
    Journal of virology (Print)
    
    J.G.D. Gall et al., "CONSTRUCTION AND CHARACTERIZATION OF HEXON-CHIMERIC ADENOVIRUSES - SPECIFICATION OF ADENOVIRUS SEROTYPE", Journal of virology (Print), 72(12), 1998, pp. 10260-10264
26. DALE IL; TUFFLEY W; CALLAGHAN R; HOLMES JA; MARTIN K; LUSCOMBE M; MISTRY P; RYDER H; STEWART AJ; CHARLTON P; TWENTYMAN PR; BEVAN P
    REVERSAL OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY XR9051, ANOVEL DIKETOPIPERAZINE DERIVATIVE
    British Journal of Cancer
    
    I.L. Dale et al., "REVERSAL OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY XR9051, ANOVEL DIKETOPIPERAZINE DERIVATIVE", British Journal of Cancer, 78(7), 1998, pp. 885-892
27. HOLFORD J; SHARP SY; MURRER BA; ABRAMS M; KELLAND LR
    IN-VITRO CIRCUMVENTION OF CISPLATIN RESISTANCE BY THE NOVEL STERICALLY HINDERED PLATINUM COMPLEX AMD473
    British Journal of Cancer
    
    J. Holford et al., "IN-VITRO CIRCUMVENTION OF CISPLATIN RESISTANCE BY THE NOVEL STERICALLY HINDERED PLATINUM COMPLEX AMD473", British Journal of Cancer, 77(3), 1998, pp. 366-373
28. BICHAT F; SOLISRECENDEZ G; POULLAIN MG; POUPON MF; KHAYAT D; BASTIAN G
    S9788 MODULATION OF P-GLYCOPROTEIN-RELATED AND MULTIDRUG-RELATED PROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY SERVIER-9788 IN DOXORUBICIN-RESISTANT MCF7 CELLS
    Biochemical pharmacology
    
    F. Bichat et al., "S9788 MODULATION OF P-GLYCOPROTEIN-RELATED AND MULTIDRUG-RELATED PROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY SERVIER-9788 IN DOXORUBICIN-RESISTANT MCF7 CELLS", Biochemical pharmacology, 56(4), 1998, pp. 497-502
29. YANG JM; SULLIVAN GF; MAKHEY DB; LAVOIE EJ; HAIT WN
    INHIBITORY EFFECT OF ALKYLATING MODULATORS ON THE FUNCTION OF P-GLYCOPROTEIN
    Oncology research
    
    J.M. Yang et al., "INHIBITORY EFFECT OF ALKYLATING MODULATORS ON THE FUNCTION OF P-GLYCOPROTEIN", Oncology research, 9(9), 1997, pp. 477-484
30. NARASAKI F; OKA M; FUKUDA M; NAKANO R; IKEDA K; TAKATANI H; TERASHI K; SODA H; YANO O; NAKAMURA T; DOYLE LA; TSURUO T; KOHNO S
    A NOVEL QUINOLINE DERIVATIVE, MS-209, OVERCOMES DRUG-RESISTANCE OF HUMAN LUNG-CANCER CELLS EXPRESSING THE MULTIDRUG RESISTANCE-ASSOCIATE PROTEIN (MRP) GENE
    Cancer chemotherapy and pharmacology
    
    F. Narasaki et al., "A NOVEL QUINOLINE DERIVATIVE, MS-209, OVERCOMES DRUG-RESISTANCE OF HUMAN LUNG-CANCER CELLS EXPRESSING THE MULTIDRUG RESISTANCE-ASSOCIATE PROTEIN (MRP) GENE", Cancer chemotherapy and pharmacology, 40(5), 1997, pp. 425-432
31. COVELLI A
    SDZ-PSC-833 - A NEW MULTIDRUG-RESISTANCE MODULATOR
    Tumori
    
    A. Covelli, "SDZ-PSC-833 - A NEW MULTIDRUG-RESISTANCE MODULATOR", Tumori, 83(5), 1997, pp. 21-24
32. EHRLICH PH; MOUSTAFA ZA; ARCHINALMATTHEIS AE; NEWMAN MJ; BAIR KW; COHEN D
    THE REVERSAL OF MULTIDRUG-RESISTANCE IN MULTICELLULAR TUMOR SPHEROIDSBY SDZ PSC-833
    Anticancer research
    
    P.H. Ehrlich et al., "THE REVERSAL OF MULTIDRUG-RESISTANCE IN MULTICELLULAR TUMOR SPHEROIDSBY SDZ PSC-833", Anticancer research, 17(1A), 1997, pp. 129-133
33. HOLMES FA; LOPEZ A; MAVLIGIT G; FRASCHINI G; FRYE D; HORTOBAGYI GN
    SECONDARY DRUG-RESISTANCE IN BREAST-CANCER - FAILURE TO REVERSE WITH ORAL NIFEDIPINE
    International journal of cancer
    
    F.A. Holmes et al., "SECONDARY DRUG-RESISTANCE IN BREAST-CANCER - FAILURE TO REVERSE WITH ORAL NIFEDIPINE", International journal of cancer, 73(2), 1997, pp. 184-186
34. PUNT CJA; VOEST EE; TUENI E; VANOOSTEROM AT; BACKX A; DEMULDER PHM; HECQUET B; LUCAS C; GERARD B; BLEIBERG H
    PHASE IB STUDY OF DOXORUBICIN IN COMBINATION WITH THE MULTIDRUG-RESISTANCE REVERSING AGENT S9788 IN ADVANCED COLORECTAL AND RENAL-CELL CANCER
    British Journal of Cancer
    
    C.J.A. Punt et al., "PHASE IB STUDY OF DOXORUBICIN IN COMBINATION WITH THE MULTIDRUG-RESISTANCE REVERSING AGENT S9788 IN ADVANCED COLORECTAL AND RENAL-CELL CANCER", British Journal of Cancer, 76(10), 1997, pp. 1376-1381
35. WATANABE T; NAITO M; KOKUBU N; TSURUO T
    REGRESSION OF ESTABLISHED TUMORS EXPRESSING P-GLYCOPROTEIN BY COMBINATIONS OF ADRIAMYCIN, CYCLOSPORINE DERIVATIVES, AND MRK-16 ANTIBODIES
    Journal of the National Cancer Institute
    
    T. Watanabe et al., "REGRESSION OF ESTABLISHED TUMORS EXPRESSING P-GLYCOPROTEIN BY COMBINATIONS OF ADRIAMYCIN, CYCLOSPORINE DERIVATIVES, AND MRK-16 ANTIBODIES", Journal of the National Cancer Institute, 89(7), 1997, pp. 512-518
36. FLANDINA C; FLUGY A; BORSELLINO N; DALESSANDRO N
    DEVELOPMENT AND PARTIAL CHARACTERIZATION OF A HUMAN T-LYMPHOBLASTIC LEUKEMIC (CCRF-CEM) CELL-LINE RESISTANT TO ETOPOSIDE - ANALYSIS OF POSSIBLE CIRCUMVENTING APPROACHES
    Journal of chemotherapy
    
    C. Flandina et al., "DEVELOPMENT AND PARTIAL CHARACTERIZATION OF A HUMAN T-LYMPHOBLASTIC LEUKEMIC (CCRF-CEM) CELL-LINE RESISTANT TO ETOPOSIDE - ANALYSIS OF POSSIBLE CIRCUMVENTING APPROACHES", Journal of chemotherapy, 8(6), 1996, pp. 465-471
37. TIMCHEVA CV; TODOROV DK
    DOES VERAPAMIL HELP OVERCOME MULTIDRUG-RESISTANCE IN TUMOR-CELL LINESAND CANCER-PATIENTS
    Journal of chemotherapy
    
    C.V. Timcheva e D.K. Todorov, "DOES VERAPAMIL HELP OVERCOME MULTIDRUG-RESISTANCE IN TUMOR-CELL LINESAND CANCER-PATIENTS", Journal of chemotherapy, 8(4), 1996, pp. 295-299
38. ALIGIANNIS N; POULI N; MARAKOS P; SKALTSOUNIS AL; LEONCE S; PIERRE A; ATASSI G
    SYNTHESIS AND BIOLOGICAL-ACTIVITY OF 4'-AZIDO-3'-CHLORO-3'-DEAMINO-4'-DEOXYDAUNORUBICIN AND CETAMIDO-3'-CHLORO-3'-DEAMINO-4'-DEOXYDAUNORUBICIN
    Bioorganic & medicinal chemistry letters
    
    N. Aligiannis et al., "SYNTHESIS AND BIOLOGICAL-ACTIVITY OF 4'-AZIDO-3'-CHLORO-3'-DEAMINO-4'-DEOXYDAUNORUBICIN AND CETAMIDO-3'-CHLORO-3'-DEAMINO-4'-DEOXYDAUNORUBICIN", Bioorganic & medicinal chemistry letters, 6(20), 1996, pp. 2473-2476
39. WATANABE T; NAKAYAMA Y; NAITO M; OHHARA T; ITOH Y; TSURUO T
    CREMOPHOR EL REVERSED MULTIDRUG-RESISTANCE IN-VITRO BUT NOT IN TUMOR-BEARING MOUSE MODELS
    Anti-cancer drugs
    
    T. Watanabe et al., "CREMOPHOR EL REVERSED MULTIDRUG-RESISTANCE IN-VITRO BUT NOT IN TUMOR-BEARING MOUSE MODELS", Anti-cancer drugs, 7(8), 1996, pp. 825-832
40. WATANABE T; NAITO M; OHHARA T; ITOH Y; COHEN D; TSURUO T
    MODULATION OF MULTIDRUG-RESISTANCE BY SDZ PSC-833 IN LEUKEMIC AND SOLID-TUMOR-BEARING MOUSE MODELS
    Japanese journal of cancer research
    
    T. Watanabe et al., "MODULATION OF MULTIDRUG-RESISTANCE BY SDZ PSC-833 IN LEUKEMIC AND SOLID-TUMOR-BEARING MOUSE MODELS", Japanese journal of cancer research, 87(2), 1996, pp. 184-193
41. SONNEVELD P; MARIE JP; HUISMAN C; VEKHOFF A; SCHOESTER M; FAUSSAT AM; VANKAPEL J; GROENEWEGEN A; CHARNICK S; ZITTOUN R; LOWENBERG B
    REVERSAL OF MULTIDRUG-RESISTANCE BY SDZ PSC-833, COMBINED WITH VAD (VINCRISTINE, DOXORUBICIN, DEXAMETHASONE) IN REFRACTORY MULTIPLE-MYELOMA- A PHASE-I STUDY
    Leukemia
    
    P. Sonneveld et al., "REVERSAL OF MULTIDRUG-RESISTANCE BY SDZ PSC-833, COMBINED WITH VAD (VINCRISTINE, DOXORUBICIN, DEXAMETHASONE) IN REFRACTORY MULTIPLE-MYELOMA- A PHASE-I STUDY", Leukemia, 10(11), 1996, pp. 1741-1750
42. BOOTE DJ; DENNIS IF; TWENTYMAN PR; OSBORNE RJ; LABURTE C; HENSEL S; SMYTH JF; BRAMPTON MH; BLEEHEN NM
    PHASE-I STUDY OF ETOPOSIDE WITH SDZ PSC 833 AS A MODULATOR OF MULTIDRUG-RESISTANCE IN PATIENTS WITH CANCER
    Journal of clinical oncology
    
    D.J. Boote et al., "PHASE-I STUDY OF ETOPOSIDE WITH SDZ PSC 833 AS A MODULATOR OF MULTIDRUG-RESISTANCE IN PATIENTS WITH CANCER", Journal of clinical oncology, 14(2), 1996, pp. 610-618
43. MICHIELI M; DAMIANI D; MICHELUTTI A; MELLI C; ERMACORA A; GEROMIN A; FANIN R; RUSSO D; BACCARANI M
    OVERCOMING PGP-RELATED MULTIDRUG-RESISTANCE - THE CYCLOSPORINE DERIVATIVE SDZ PSC-833 CAN ABOLISH THE RESISTANCE TO METHOXY-MORPHOLYNIL-DOXORUBICIN
    Haematologica
    
    M. Michieli et al., "OVERCOMING PGP-RELATED MULTIDRUG-RESISTANCE - THE CYCLOSPORINE DERIVATIVE SDZ PSC-833 CAN ABOLISH THE RESISTANCE TO METHOXY-MORPHOLYNIL-DOXORUBICIN", Haematologica, 81(4), 1996, pp. 295-301
44. OHISHI I; MORINAGA Y; OHSUMI K; NAKAGAWA R; SUGA E; TSUJI T; AKIYAMA Y; TSURUO T
    POTENTIATION OF ANTITUMOR AND ANTIMETASTATIC ACTIVITIES OF ADRIAMYCINBY A NOVEL N-ALKYLATED DIHYDROPYRIDINE, AC394, AND ITS ENANTIOMERS INCOLON CANCER-BEARING MICE
    Cancer chemotherapy and pharmacology
    
    I. Ohishi et al., "POTENTIATION OF ANTITUMOR AND ANTIMETASTATIC ACTIVITIES OF ADRIAMYCINBY A NOVEL N-ALKYLATED DIHYDROPYRIDINE, AC394, AND ITS ENANTIOMERS INCOLON CANCER-BEARING MICE", Cancer chemotherapy and pharmacology, 38(5), 1996, pp. 446-452
45. NOOTER K; STOTER G
    MOLECULAR MECHANISMS OF MULTIDRUG-RESISTANCE IN CANCER-CHEMOTHERAPY
    Pathology research and practice
    
    K. Nooter e G. Stoter, "MOLECULAR MECHANISMS OF MULTIDRUG-RESISTANCE IN CANCER-CHEMOTHERAPY", Pathology research and practice, 192(7), 1996, pp. 768-780
46. QUESADA AR; BARBACID MM; MIRA E; ARACIL M; MARQUEZ G
    CHEMOSENSITIZATION AND DRUG ACCUMULATION ASSAYS AS COMPLEMENTARY METHODS FOR THE SCREENING OF MULTIDRUG-RESISTANCE REVERSAL AGENTS
    Cancer letters
    
    A.R. Quesada et al., "CHEMOSENSITIZATION AND DRUG ACCUMULATION ASSAYS AS COMPLEMENTARY METHODS FOR THE SCREENING OF MULTIDRUG-RESISTANCE REVERSAL AGENTS", Cancer letters, 99(1), 1996, pp. 109-114
47. JOLY P; LALLEMAND A; OUMHAMED Z; TRENTESAUX C; IDOINE O; DESPLACES A
    EFFECTS OF VERAPAMIL AND S9788 ON MDR-1 MESSENGER-RNA EXPRESSION STUDIED BY IN-SITU HYBRIDIZATION
    Anticancer research
    
    P. Joly et al., "EFFECTS OF VERAPAMIL AND S9788 ON MDR-1 MESSENGER-RNA EXPRESSION STUDIED BY IN-SITU HYBRIDIZATION", Anticancer research, 16(6B), 1996, pp. 3609-3614
48. DAVEY MW; HARGRAVE RM; DAVEY RA
    COMPARISON OF DRUG ACCUMULATION IN P-GLYCOPROTEIN-EXPRESSING AND MRP-EXPRESSING HUMAN LEUKEMIA-CELLS
    Leukemia research
    
    M.W. Davey et al., "COMPARISON OF DRUG ACCUMULATION IN P-GLYCOPROTEIN-EXPRESSING AND MRP-EXPRESSING HUMAN LEUKEMIA-CELLS", Leukemia research, 20(8), 1996, pp. 657-664
49. MANKHETKORN S; DUBRU F; HESSCHENBROUCK J; FIALLO M; GARNIERSUILLEROT A
    RELATION AMONG THE RESISTANCE FACTOR, KINETICS OF UPTAKE, AND KINETICS OF THE P-GLYCOPROTEIN-MEDIATED EFFLUX OF DOXORUBICIN, DAUNORUBICIN, 8-(S)-FLUOROIDARUBICIN, AND IDARUBICIN IN MULTIDRUG-RESISTANT K562 CELLS
    Molecular pharmacology
    
    S. Mankhetkorn et al., "RELATION AMONG THE RESISTANCE FACTOR, KINETICS OF UPTAKE, AND KINETICS OF THE P-GLYCOPROTEIN-MEDIATED EFFLUX OF DOXORUBICIN, DAUNORUBICIN, 8-(S)-FLUOROIDARUBICIN, AND IDARUBICIN IN MULTIDRUG-RESISTANT K562 CELLS", Molecular pharmacology, 49(3), 1996, pp. 532-539
50. TAKESHITA H; GEBHARDT MC; SPRINGFIELD DS; KUSUZAKI K; MANKIN HJ
    EXPERIMENTAL-MODELS FOR THE STUDY OF DRUG-RESISTANCE IN OSTEOSARCOMA - P-GLYCOPROTEIN-POSITIVE, MURINE OSTEOSARCOMA CELL-LINES
    Journal of bone and joint surgery. American volume
    
    H. Takeshita et al., "EXPERIMENTAL-MODELS FOR THE STUDY OF DRUG-RESISTANCE IN OSTEOSARCOMA - P-GLYCOPROTEIN-POSITIVE, MURINE OSTEOSARCOMA CELL-LINES", Journal of bone and joint surgery. American volume, 78A(3), 1996, pp. 366-375
51. DEMMER A; DUNN T; HOOF T; KUBESCH P; TUMMLER B
    COMPETITIVE-INHIBITION OF PHOTOAFFINITY-LABELING OF P-GLYCOPROTEIN BYANTICANCER DRUGS AND MODULATORS INCLUDING S9788
    European journal of pharmacology
    
    A. Demmer et al., "COMPETITIVE-INHIBITION OF PHOTOAFFINITY-LABELING OF P-GLYCOPROTEIN BYANTICANCER DRUGS AND MODULATORS INCLUDING S9788", European journal of pharmacology, 315(3), 1996, pp. 339-343
52. DANTZIG AH; SHEPARD RL; CAO J; LAW KL; EHLHARDT WJ; BAUGHMAN TM; BUMOL TF; STARLING JJ
    REVERSAL OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY A POTENT CYCLOPROPYLDIBENZOSUBERANE MODULATOR, LY335979
    Cancer research
    
    A.H. Dantzig et al., "REVERSAL OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY A POTENT CYCLOPROPYLDIBENZOSUBERANE MODULATOR, LY335979", Cancer research, 56(18), 1996, pp. 4171-4179
53. SHARP SY; ROGERS PM; KELLAND LR
    TRANSPORT OF CISPLATIN AND BIS-ACETATO-AMMINE-DICHLOROCYCLOHEXYL-AMINE PLATINUM(IV) (JM216) IN HUMAN OVARIAN-CARCINOMA CELL-LINES - IDENTIFICATION OF A PLASMA-MEMBRANE PROTEIN ASSOCIATED WITH CISPLATIN RESISTANCE
    Clinical cancer research
    
    S.Y. Sharp et al., "TRANSPORT OF CISPLATIN AND BIS-ACETATO-AMMINE-DICHLOROCYCLOHEXYL-AMINE PLATINUM(IV) (JM216) IN HUMAN OVARIAN-CARCINOMA CELL-LINES - IDENTIFICATION OF A PLASMA-MEMBRANE PROTEIN ASSOCIATED WITH CISPLATIN RESISTANCE", Clinical cancer research, 1(9), 1995, pp. 981-989
54. PFISTER JR; MAKRA F; MUEHLDORF AV; WU H; NELSON JT; CHEUNG P; BRUNO NA; CASEY SM; ZUTSHI N; SLATE DL
    METHANODIBENZOSUBERYLPIPERAZINES AS POTENT MULTIDRUG-RESISTANCE REVERSAL AGENTS
    Bioorganic & medicinal chemistry letters
    
    J.R. Pfister et al., "METHANODIBENZOSUBERYLPIPERAZINES AS POTENT MULTIDRUG-RESISTANCE REVERSAL AGENTS", Bioorganic & medicinal chemistry letters, 5(21), 1995, pp. 2473-2476
55. BERTRAM J; PALFNER K; KILLIAN M; BRYSCH W; SCHLINGENSIEPEN KH; HIDDEMANN W; KNEBA M
    REVERSAL OF MULTIPLE-DRUG RESISTANCE IN-VITRO BY PHOSPHORATHIOATE OLIGONUCLEOTIDES AND RIBOZYMES
    Anti-cancer drugs
    
    J. Bertram et al., "REVERSAL OF MULTIPLE-DRUG RESISTANCE IN-VITRO BY PHOSPHORATHIOATE OLIGONUCLEOTIDES AND RIBOZYMES", Anti-cancer drugs, 6(1), 1995, pp. 124-134
56. SOUDON J; BERLION M; LUCAS C; HADDAD P; BIZZARI JP; CALVO F
    IN-VITRO ACTIVITY OF S-9788 ON A MULTIDRUG-RESISTANT LEUKEMIC-CELL LINE AND ON NORMAL HEMATOPOIETIC CELLS-REVERSAL OF MULTIDRUG-RESISTANCE BY SERA FROM PHASE-I TREATED PATIENTS
    Cancer chemotherapy and pharmacology
    
    J. Soudon et al., "IN-VITRO ACTIVITY OF S-9788 ON A MULTIDRUG-RESISTANT LEUKEMIC-CELL LINE AND ON NORMAL HEMATOPOIETIC CELLS-REVERSAL OF MULTIDRUG-RESISTANCE BY SERA FROM PHASE-I TREATED PATIENTS", Cancer chemotherapy and pharmacology, 36(3), 1995, pp. 195-203
57. WATANABE T; TSUGE H; OHHARA T; NAITO M; TSURUO T
    COMPARATIVE-STUDY ON REVERSAL EFFICACY OF SDZ PSC-833, CYCLOSPORINE-AAND VERAPAMIL ON MULTIDRUG-RESISTANCE IN-VITRO AND IN-VIVO
    Acta oncologica
    
    T. Watanabe et al., "COMPARATIVE-STUDY ON REVERSAL EFFICACY OF SDZ PSC-833, CYCLOSPORINE-AAND VERAPAMIL ON MULTIDRUG-RESISTANCE IN-VITRO AND IN-VIVO", Acta oncologica, 34(2), 1995, pp. 235-241
58. OUDARD S; THIOUNN N; COPEL LB; CHAUVENET L; LAURAINE EP; BERNADOU A
    RESISTANCE TO CHEMOTHERAPY IN RENAL-CELL CANCER AND THERAPEUTIC PROSPECTIVES
    Journal d'urologie
    
    S. Oudard et al., "RESISTANCE TO CHEMOTHERAPY IN RENAL-CELL CANCER AND THERAPEUTIC PROSPECTIVES", Journal d'urologie, 101(3), 1995, pp. 122-124
59. SCHWABE K; STEINHEIDER G; LAWEN A; TRABER R; HILDEBRANDT A
    REVERSAL OF MULTIDRUG-RESISTANCE BY NOVEL CYCLOSPORINE-A ANALOGS AND THE CYCLOPEPTIDE SDZ-214-103 BIOSYNTHESIZED IN-VITRO
    Journal of cancer research and clinical oncology
    
    K. Schwabe et al., "REVERSAL OF MULTIDRUG-RESISTANCE BY NOVEL CYCLOSPORINE-A ANALOGS AND THE CYCLOPEPTIDE SDZ-214-103 BIOSYNTHESIZED IN-VITRO", Journal of cancer research and clinical oncology, 121(7), 1995, pp. 407-412
60. ELZAYAT AAE; IZQUIERDO MA; CLARK GM; VONHOFF DD
    ACTIVITY OF THE MORPHOLINO ANTHRACYCLINE MINO-3'-MORPHOLINO-13-DEOXO-10-HYDROXYCARMINOMYCIN (MX2) AGAINST HUMAN TUMOR COLONY-FORMING-UNITS IN-VITRO
    Investigational new drugs
    
    A.A.E. Elzayat et al., "ACTIVITY OF THE MORPHOLINO ANTHRACYCLINE MINO-3'-MORPHOLINO-13-DEOXO-10-HYDROXYCARMINOMYCIN (MX2) AGAINST HUMAN TUMOR COLONY-FORMING-UNITS IN-VITRO", Investigational new drugs, 13(2), 1995, pp. 125-131
61. TESTI R; MATTII L; DISIMONE D; ZACCARO L; MALVALDI G; GRASSI B; PETRINI M
    EVALUATION OF RESISTANCE INDEX OF SEVERAL ANTICANCER AGENTS ON PARENTAL AND RESISTANT P-388 CELL-LINES
    Leukemia research
    
    R. Testi et al., "EVALUATION OF RESISTANCE INDEX OF SEVERAL ANTICANCER AGENTS ON PARENTAL AND RESISTANT P-388 CELL-LINES", Leukemia research, 19(4), 1995, pp. 257-261
62. HERMAN LW; SHARMA V; KRONAUGE JF; BARBARICS E; HERMAN LA; PIWNICAWORMS D
    NOVEL HEXAKIS(ARENEISONITRILE)TECHNETIUM(I) COMPLEXES AS RADIOLIGANDSTARGETED TO THE MULTIDRUG-RESISTANCE P-GLYCOPROTEIN
    Journal of medicinal chemistry
    
    L.W. Herman et al., "NOVEL HEXAKIS(ARENEISONITRILE)TECHNETIUM(I) COMPLEXES AS RADIOLIGANDSTARGETED TO THE MULTIDRUG-RESISTANCE P-GLYCOPROTEIN", Journal of medicinal chemistry, 38(15), 1995, pp. 2955-2963
63. SCHINKEL AH; WAGENAAR E; VANDEEMTER L; MOL CAAM; BORST P
    ABSENCE OF THE MDR1A P-GLYCOPROTEIN IN MICE AFFECTS TISSUE DISTRIBUTION AND PHARMACOKINETICS OF DEXAMETHASONE, DIGOXIN, AND CYCLOSPORINE-A
    The Journal of clinical investigation
    
    A.H. Schinkel et al., "ABSENCE OF THE MDR1A P-GLYCOPROTEIN IN MICE AFFECTS TISSUE DISTRIBUTION AND PHARMACOKINETICS OF DEXAMETHASONE, DIGOXIN, AND CYCLOSPORINE-A", The Journal of clinical investigation, 96(4), 1995, pp. 1698-1705
64. NAFZIGER J; AVERLAND G; BERTOUNESQUE E; GAUDEL G; MONNERET C
    SYNTHESIS AND ANTIPROLIFERATIVE EFFECTS OF A 4'-MORPHOLINO-9-METHYL ANTHRACYCLINE
    Journal of antibiotics
    
    J. Nafziger et al., "SYNTHESIS AND ANTIPROLIFERATIVE EFFECTS OF A 4'-MORPHOLINO-9-METHYL ANTHRACYCLINE", Journal of antibiotics, 48(10), 1995, pp. 1185-1187
65. DIDIER AD; LOOR F
    DECREASED BIOTOLERABILITY FOR IVERMECTIN AND CYCLOSPORINE-A IN MICE EXPOSED TO POTENT P-GLYCOPROTEIN INHIBITORS
    International journal of cancer
    
    A.D. Didier e F. Loor, "DECREASED BIOTOLERABILITY FOR IVERMECTIN AND CYCLOSPORINE-A IN MICE EXPOSED TO POTENT P-GLYCOPROTEIN INHIBITORS", International journal of cancer, 63(2), 1995, pp. 263-267
66. GIANDOMENICO CM; ABRAMS MJ; MURRER BA; VOLLANO JF; RHEINHEIMER MI; WYER SB; BOSSARD GE; HIGGINS JD
    CARBOXYLATION OF KINETICALLY INERT PLATINUM(IV) HYDROXY COMPLEXES - AN ENTREE INTO ORALLY-ACTIVE PLATINUM(IV) ANTITUMOR AGENTS
    Inorganic chemistry
    
    C.M. Giandomenico et al., "CARBOXYLATION OF KINETICALLY INERT PLATINUM(IV) HYDROXY COMPLEXES - AN ENTREE INTO ORALLY-ACTIVE PLATINUM(IV) ANTITUMOR AGENTS", Inorganic chemistry, 34(5), 1995, pp. 1015-1021
67. OHSUMI K; OHISHI K; MORINAGA Y; NAKAGAWA R; SUGA Y; SEKIYAMA T; AKIYAMA Y; TSUJI T; TSURUO T
    N-ALKYLATED 1,4-DIHYDROPYRIDINES - NEW AGENTS TO OVERCOME MULTIDRUG-RESISTANCE
    Chemical and Pharmaceutical Bulletin
    
    K. Ohsumi et al., "N-ALKYLATED 1,4-DIHYDROPYRIDINES - NEW AGENTS TO OVERCOME MULTIDRUG-RESISTANCE", Chemical and Pharmaceutical Bulletin, 43(5), 1995, pp. 818-828
68. DALTON WS; CROWLEY JJ; SALMON SS; GROGAN TM; LAUFMAN LR; WEISS GR; BONNET JD
    A PHASE-III RANDOMIZED STUDY OF ORAL VERAPAMIL AS A CHEMOSENSITIZER TO REVERSE DRUG-RESISTANCE IN PATIENTS WITH REFRACTORY MYELOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    Cancer
    
    W.S. Dalton et al., "A PHASE-III RANDOMIZED STUDY OF ORAL VERAPAMIL AS A CHEMOSENSITIZER TO REVERSE DRUG-RESISTANCE IN PATIENTS WITH REFRACTORY MYELOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Cancer, 75(3), 1995, pp. 815-820
69. LUDESCHER C; EISTERER W; HILBE W; HOFMANN J; THALER J
    DECREASED POTENCY OF MDR-MODULATORS UNDER SERUM CONDITIONS DETERMINEDBY A FUNCTIONAL ASSAY
    British Journal of Haematology
    
    C. Ludescher et al., "DECREASED POTENCY OF MDR-MODULATORS UNDER SERUM CONDITIONS DETERMINEDBY A FUNCTIONAL ASSAY", British Journal of Haematology, 91(3), 1995, pp. 652-657
70. COWIE FJ; PINKERTON CR; PHILLIPS M; DICK G; JUDSON I; MCCARTHY PT; FLANAGAN RJ
    CONTINUOUS-INFUSION VERAPAMIL WITH ETOPOSIDE IN RELAPSED OR RESISTANTPEDIATRIC CANCERS
    British Journal of Cancer
    
    F.J. Cowie et al., "CONTINUOUS-INFUSION VERAPAMIL WITH ETOPOSIDE IN RELAPSED OR RESISTANTPEDIATRIC CANCERS", British Journal of Cancer, 71(4), 1995, pp. 877-881
71. PIWNICAWORMS D; RAO VV; KRONAUGE JF; CROOP JM
    CHARACTERIZATION OF MULTIDRUG-RESISTANCE P-GLYCOPROTEIN TRANSPORT FUNCTION WITH AN ORGANOTECHNETIUM CATION
    Biochemistry
    
    D. Piwnicaworms et al., "CHARACTERIZATION OF MULTIDRUG-RESISTANCE P-GLYCOPROTEIN TRANSPORT FUNCTION WITH AN ORGANOTECHNETIUM CATION", Biochemistry, 34(38), 1995, pp. 12210-12220
72. BORREL MN; FIALLO M; VERESS I; GARNIERSUILLEROT A
    THE EFFECT OF CROWN-ETHERS, TETRAALKYLAMMONIUM SALTS, AND POLYOXYETHYLENE AMPHIPHILES ON PIRARUBICIN INCORPORATION IN K562 RESISTANT CELLS
    Biochemical pharmacology
    
    M.N. Borrel et al., "THE EFFECT OF CROWN-ETHERS, TETRAALKYLAMMONIUM SALTS, AND POLYOXYETHYLENE AMPHIPHILES ON PIRARUBICIN INCORPORATION IN K562 RESISTANT CELLS", Biochemical pharmacology, 50(12), 1995, pp. 2069-2076
73. VILADKAR A; CHITNIS M
    IN-VITRO EFFECTS OF PENTOXIFYLLINE AND DOXORUBICIN ON CELL-SURVIVAL AND DNA-DAMAGE IN SENSITIVE AND MDR-P388 LEUKEMIA-CELLS
    Cancer biotherapy
    
    A. Viladkar e M. Chitnis, "IN-VITRO EFFECTS OF PENTOXIFYLLINE AND DOXORUBICIN ON CELL-SURVIVAL AND DNA-DAMAGE IN SENSITIVE AND MDR-P388 LEUKEMIA-CELLS", Cancer biotherapy, 9(2), 1994, pp. 143-151
74. LEONCE S; PIERRE A; PEREZ V; GUILBAUD N; KRAUSBERTHIER L; GENTON A; LOMBET A; PEGLION JL; ATASSI G
    MULTIDRUG-RESISTANCE CIRCUMVENTION AND INHIBITION OF [H-3] AZIDOPINE PHOTOLABELING OF P-GLYCOPROTEIN BY NEW DIHYDROPYRIDINE DERIVATIVES DISPLAYING A LOW-AFFINITY FOR CALCIUM CHANNELS
    International journal of oncology
    
    S. Leonce et al., "MULTIDRUG-RESISTANCE CIRCUMVENTION AND INHIBITION OF [H-3] AZIDOPINE PHOTOLABELING OF P-GLYCOPROTEIN BY NEW DIHYDROPYRIDINE DERIVATIVES DISPLAYING A LOW-AFFINITY FOR CALCIUM CHANNELS", International journal of oncology, 4(6), 1994, pp. 1243-1250
75. JACHEZ B; BOESCH D; EMMER G; LOOR F
    SDZ 280-125 - A CYCLOPEPTOLIDE ENDOWED WITH AN IN-VITRO CYCLOSPORINE A-LIKE PROFILE OF ACTIVITY FOR THE REVERSION OF THE P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE OF TUMOR-CELLS
    Anti-cancer drugs
    
    B. Jachez et al., "SDZ 280-125 - A CYCLOPEPTOLIDE ENDOWED WITH AN IN-VITRO CYCLOSPORINE A-LIKE PROFILE OF ACTIVITY FOR THE REVERSION OF THE P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE OF TUMOR-CELLS", Anti-cancer drugs, 5(3), 1994, pp. 313-320
76. BARANCIK M; POLEKOVA L; MRAZOVA T; BREIER A; STANKOVICOVA T; SLEZAK J
    REVERSAL EFFECTS OF SEVERAL CA2-ENTRY BLOCKERS, NEUROLEPTICS AND LOCAL-ANESTHETICS ON P-GLYCOPROTEIN-MEDIATED VINCRISTINE RESISTANCE OF L1210()VCR MOUSE LEUKEMIC-CELL LINE/
    Drugs under experimental and clinical research
    
    M. Barancik et al., "REVERSAL EFFECTS OF SEVERAL CA2-ENTRY BLOCKERS, NEUROLEPTICS AND LOCAL-ANESTHETICS ON P-GLYCOPROTEIN-MEDIATED VINCRISTINE RESISTANCE OF L1210()VCR MOUSE LEUKEMIC-CELL LINE/", Drugs under experimental and clinical research, 20(1), 1994, pp. 13-18
77. SHARP SY; MISTRY P; VALENTI MR; BRYANT AP; KELLAND LR
    SELECTIVE POTENTIATION OF PLATINUM DRUG CYTOTOXICITY IN CISPLATIN-SENSITIVE AND CISPLATIN-RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINES BY AMPHOTERICIN-B
    Cancer chemotherapy and pharmacology
    
    S.Y. Sharp et al., "SELECTIVE POTENTIATION OF PLATINUM DRUG CYTOTOXICITY IN CISPLATIN-SENSITIVE AND CISPLATIN-RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINES BY AMPHOTERICIN-B", Cancer chemotherapy and pharmacology, 35(2), 1994, pp. 137-143
78. WANG L; YANG CPH; HORWITZ SB; TRAIL PA; CASAZZA AM
    REVERSAL OF THE HUMAN AND MURINE MULTIDRUG-RESISTANCE PHENOTYPE WITH MEGESTROL-ACETATE
    Cancer chemotherapy and pharmacology
    
    L. Wang et al., "REVERSAL OF THE HUMAN AND MURINE MULTIDRUG-RESISTANCE PHENOTYPE WITH MEGESTROL-ACETATE", Cancer chemotherapy and pharmacology, 34(2), 1994, pp. 96-102
79. HILL BT; HOSKING LK
    DIFFERENTIAL EFFECTIVENESS OF A RANGE OF NOVEL DRUG-RESISTANCE MODULATORS, RELATIVE TO VERAPAMIL, IN INFLUENCING VINBLASTINE OR TENIPOSIDE CYTOTOXICITY IN HUMAN LYMPHOBLASTOID CCRF-CEM SUBLINES EXPRESSING CLASSIC OR ATYPICAL MULTIDRUG-RESISTANCE
    Cancer chemotherapy and pharmacology
    
    B.T. Hill e L.K. Hosking, "DIFFERENTIAL EFFECTIVENESS OF A RANGE OF NOVEL DRUG-RESISTANCE MODULATORS, RELATIVE TO VERAPAMIL, IN INFLUENCING VINBLASTINE OR TENIPOSIDE CYTOTOXICITY IN HUMAN LYMPHOBLASTOID CCRF-CEM SUBLINES EXPRESSING CLASSIC OR ATYPICAL MULTIDRUG-RESISTANCE", Cancer chemotherapy and pharmacology, 33(4), 1994, pp. 317-324
80. KRAUSBERTHIER L; GUILBAUD N; PEGLION JL; LEONCE S; LOMBET A; PIERRE A; ATASSI G
    IN-VIVO REVERSAL OF MULTIDRUG-RESISTANCE BY 2 NEW DIHYDROPYRIDINE DERIVATIVES, S16317 AND S16324
    Acta oncologica
    
    L. Krausberthier et al., "IN-VIVO REVERSAL OF MULTIDRUG-RESISTANCE BY 2 NEW DIHYDROPYRIDINE DERIVATIVES, S16317 AND S16324", Acta oncologica, 33(6), 1994, pp. 631-637
81. SIDDIK ZH; THAI G; YOSHIDA M; ZHANG YP; KHOKHAR AR
    TETRAVALENT PLATINUM COMPLEXES WITH AMMINE AMINE CARRIER LIGAND CONFIGURATION - CIRCUMVENTION OF PLATINUM RESISTANCE IN-VIVO
    Anti-cancer drug design
    
    Z.H. Siddik et al., "TETRAVALENT PLATINUM COMPLEXES WITH AMMINE AMINE CARRIER LIGAND CONFIGURATION - CIRCUMVENTION OF PLATINUM RESISTANCE IN-VIVO", Anti-cancer drug design, 9(6), 1994, pp. 495-509
82. DEMETZOS C; SKALTSOUNIS AL; MICHEL S; TILLEQUIN F; KOCH M; ANSTETT M; LEONCE S; PIERRE A; ATASSI G
    SYNTHESIS AND BIOLOGICAL-ACTIVITY OF 3'-DEAMINO-3'-HALOANTHRACYCLINES
    Anti-cancer drug design
    
    C. Demetzos et al., "SYNTHESIS AND BIOLOGICAL-ACTIVITY OF 3'-DEAMINO-3'-HALOANTHRACYCLINES", Anti-cancer drug design, 9(2), 1994, pp. 129-137
83. SEBILLE S; MORJANI H; POULLAIN MG; MANFAIT M
    EFFECT OF S9788, CYCLOSPORINE-A AND VERAPAMIL ON INTRACELLULAR-DISTRIBUTION OF THP-DOXORUBICIN IN MULTIDRUG-RESISTANT K562 TUMOR-CELLS, AS STUDIED BY LASER CONFOCAL MICROSPECTROFLUOROMETRY
    Anticancer research
    
    S. Sebille et al., "EFFECT OF S9788, CYCLOSPORINE-A AND VERAPAMIL ON INTRACELLULAR-DISTRIBUTION OF THP-DOXORUBICIN IN MULTIDRUG-RESISTANT K562 TUMOR-CELLS, AS STUDIED BY LASER CONFOCAL MICROSPECTROFLUOROMETRY", Anticancer research, 14(6A), 1994, pp. 2389-2393
84. MASLAK P; HEGEWISCHBECKER S; GODFREY L; ANDREEFF M
    FLOW CYTOMETRIC DETERMINATION OF THE MULTIDRUG-RESISTANT PHENOTYPE INACUTE-LEUKEMIA
    Cytometry
    
    P. Maslak et al., "FLOW CYTOMETRIC DETERMINATION OF THE MULTIDRUG-RESISTANT PHENOTYPE INACUTE-LEUKEMIA", Cytometry, 17(1), 1994, pp. 84-93
85. POMMERENKE E; MATTERN J; VOLM M
    MODULATION OF DOXORUBICIN-TOXICITY BY TAMOXIFEN IN MULTIDRUG-RESISTANT TUMOR-CELLS IN-VITRO AND IN-VIVO
    Journal of cancer research and clinical oncology
    
    E. Pommerenke et al., "MODULATION OF DOXORUBICIN-TOXICITY BY TAMOXIFEN IN MULTIDRUG-RESISTANT TUMOR-CELLS IN-VITRO AND IN-VIVO", Journal of cancer research and clinical oncology, 120(7), 1994, pp. 422-426
86. NOOTER K; SONNEVELD P
    CLINICAL RELEVANCE OF P-GLYCOPROTEIN EXPRESSION IN HEMATOLOGICAL MALIGNANCIES
    Leukemia research
    
    K. Nooter e P. Sonneveld, "CLINICAL RELEVANCE OF P-GLYCOPROTEIN EXPRESSION IN HEMATOLOGICAL MALIGNANCIES", Leukemia research, 18(4), 1994, pp. 233-243
87. KIWIT JCW; HERTEL A; MATUSCHEK AE
    REVERSAL OF CHEMORESISTANCE IN MALIGNANT GLIOMAS BY CALCIUM-ANTAGONISTS - CORRELATION WITH THE EXPRESSION OF MULTIDRUG-RESISTANT P-GLYCOPROTEIN
    Journal of neurosurgery
    
    J.C.W. Kiwit et al., "REVERSAL OF CHEMORESISTANCE IN MALIGNANT GLIOMAS BY CALCIUM-ANTAGONISTS - CORRELATION WITH THE EXPRESSION OF MULTIDRUG-RESISTANT P-GLYCOPROTEIN", Journal of neurosurgery, 81(4), 1994, pp. 587-594
88. EMMER G; GRASSBERGER MA; SCHULZ G; BOESCH D; GAVERIAUX C; LOOR F
    DERIVATIVES OF A NOVEL CYCLOPEPTOLIDE .2. SYNTHESIS, ACTIVITY AGAINSTMULTIDRUG-RESISTANCE IN CHO AND KB CELLS IN-VITRO, AND STRUCTURE-ACTIVITY-RELATIONSHIPS
    Journal of medicinal chemistry
    
    G. Emmer et al., "DERIVATIVES OF A NOVEL CYCLOPEPTOLIDE .2. SYNTHESIS, ACTIVITY AGAINSTMULTIDRUG-RESISTANCE IN CHO AND KB CELLS IN-VITRO, AND STRUCTURE-ACTIVITY-RELATIONSHIPS", Journal of medicinal chemistry, 37(13), 1994, pp. 1918-1928
89. BOKEMEYER C; DUNN T; HARSTRICK A; LERCH T; POLIWODA H; SCHMOLL HJ
    MODULATION OF CYTOSTATIC DRUGS BY NIFEDIPINE IN 2 HETEROTRANSPLANTED HUMAN TESTICULAR-CANCER CELL-LINES DIFFERING IN THEIR SENSITIVITY TO STANDARD AGENTS
    International journal of cancer
    
    C. Bokemeyer et al., "MODULATION OF CYTOSTATIC DRUGS BY NIFEDIPINE IN 2 HETEROTRANSPLANTED HUMAN TESTICULAR-CANCER CELL-LINES DIFFERING IN THEIR SENSITIVITY TO STANDARD AGENTS", International journal of cancer, 56(3), 1994, pp. 452-456
90. BORREL MN; FIALLO M; PRIEBE W; GARNIERSUILLEROT A
    P-GLYCOPROTEIN-MEDIATED EFFLUX OF HYDROXYRUBICIN, A NEUTRAL ANTHRACYCLINE DERIVATIVE, IN RESISTANT K562 CELLS
    FEBS letters
    
    M.N. Borrel et al., "P-GLYCOPROTEIN-MEDIATED EFFLUX OF HYDROXYRUBICIN, A NEUTRAL ANTHRACYCLINE DERIVATIVE, IN RESISTANT K562 CELLS", FEBS letters, 356(2-3), 1994, pp. 287-290
91. GRUOL DJ; ZEE MC; TROTTER J; BOURGEOIS S
    REVERSAL OF MULTIDRUG-RESISTANCE BY RU-486
    Cancer research
    
    D.J. Gruol et al., "REVERSAL OF MULTIDRUG-RESISTANCE BY RU-486", Cancer research, 54(12), 1994, pp. 3088-3091
92. OUMHAMED Z; BERLION M; MILLOTBROGLIO C; DUFER J; JOLY P; BIZZARI JP; DESPLACES A
    QUANTITATIVE CYTOLOGICAL STUDY OF THE ACT IVITY OF A NEW RESISTANCE MODULATOR, S-9788, ON HUMAN LEUKEMIC-CELLS USING MULTIPARAMETRIC IMAGE-ANALYSIS
    Bulletin du cancer
    
    Z. Oumhamed et al., "QUANTITATIVE CYTOLOGICAL STUDY OF THE ACT IVITY OF A NEW RESISTANCE MODULATOR, S-9788, ON HUMAN LEUKEMIC-CELLS USING MULTIPARAMETRIC IMAGE-ANALYSIS", Bulletin du cancer, 81(3), 1994, pp. 203-211
93. BIZZARI JP
    PHARMACOLOGICAL PROPERTIES OF S9788, A NE W MULTIDRUG-RESISTANCE MODULATOR
    Bulletin du cancer
    
    J.P. Bizzari, "PHARMACOLOGICAL PROPERTIES OF S9788, A NE W MULTIDRUG-RESISTANCE MODULATOR", Bulletin du cancer, 81(2), 1994, pp. 93-103
94. MERLIN JL; MARCHAL S; RAMACCI C; LUCAS C; PARAIRE M; POULLAIN MG
    TIME-SCHEDULE DEPENDENT REVERSION OF MULTIDRUG-RESISTANCE BY S9788 INHUMAN TUMOR-CELL LINES
    Bulletin du cancer
    
    J.L. Merlin et al., "TIME-SCHEDULE DEPENDENT REVERSION OF MULTIDRUG-RESISTANCE BY S9788 INHUMAN TUMOR-CELL LINES", Bulletin du cancer, 81(10), 1994, pp. 906-909
95. SHARP SY; ROWLANDS MG; JARMAN M; KELLAND LR
    EFFECTS OF A NEW ANTIESTROGEN, IDOXIFENE, ON CISPLATIN-SENSITIVE AND DOXORUBICIN-SENSITIVE AND DOXORUBICIN-RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINES
    British Journal of Cancer
    
    S.Y. Sharp et al., "EFFECTS OF A NEW ANTIESTROGEN, IDOXIFENE, ON CISPLATIN-SENSITIVE AND DOXORUBICIN-SENSITIVE AND DOXORUBICIN-RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINES", British Journal of Cancer, 70(3), 1994, pp. 409-414
96. MERLIN JL; GUERCI A; MARCHAL S; MISSOUM N; RAMACCI C; HUMBERT JC; TSURUO T; GUERCI O
    COMPARATIVE-EVALUATION OF S9788, VERAPAMIL, AND CYCLOSPORINE-A IN K562 HUMAN LEUKEMIA-CELL LINES AND IN P-GLYCOPROTEIN-EXPRESSING SAMPLES PATIENTS WITH HEMATOLOGIC MALIGNANCIES
    Blood
    
    J.L. Merlin et al., "COMPARATIVE-EVALUATION OF S9788, VERAPAMIL, AND CYCLOSPORINE-A IN K562 HUMAN LEUKEMIA-CELL LINES AND IN P-GLYCOPROTEIN-EXPRESSING SAMPLES PATIENTS WITH HEMATOLOGIC MALIGNANCIES", Blood, 84(1), 1994, pp. 262-269
97. KAJIJI S; DRESLIN JA; GRIZZUTI K; GROS P
    STRUCTURALLY DISTINCT MDR MODULATORS SHOW SPECIFIC PATTERNS OF REVERSAL AGAINST P-GLYCOPROTEINS BEARING UNIQUE MUTATIONS AT SERINE(939 941)/
    Biochemistry
    
    S. Kajiji et al., "STRUCTURALLY DISTINCT MDR MODULATORS SHOW SPECIFIC PATTERNS OF REVERSAL AGAINST P-GLYCOPROTEINS BEARING UNIQUE MUTATIONS AT SERINE(939 941)/", Biochemistry, 33(17), 1994, pp. 5041-5048
98. HATANO T; OHKAWA K; MATSUDA M
    CYTOTOXIC EFFECT OF THE PROTEIN-DOXORUBICIN CONJUGATES ON THE MULTIDRUG-RESISTANT HUMAN MYELOGENOUS LEUKEMIA-CELL LINE, K562, IN-VITRO
    Tumor biology
    
    T. Hatano et al., "CYTOTOXIC EFFECT OF THE PROTEIN-DOXORUBICIN CONJUGATES ON THE MULTIDRUG-RESISTANT HUMAN MYELOGENOUS LEUKEMIA-CELL LINE, K562, IN-VITRO", Tumor biology, 14(5), 1993, pp. 288-294
99. PETRINI M; MATTII L; VALENTINI P; SABBATINI ARM; GRASSI B; GRANDI M
    IDARUBICIN IS ACTIVE ON MDR CELLS - EVALUATION OF DNA-SYNTHESIS INHIBITION ON P388 CELL-LINES
    Annals of hematology
    
    M. Petrini et al., "IDARUBICIN IS ACTIVE ON MDR CELLS - EVALUATION OF DNA-SYNTHESIS INHIBITION ON P388 CELL-LINES", Annals of hematology, 67(5), 1993, pp. 227-230
100. NOOTER K; SONNEVELD P
     MULTIDRUG-RESISTANCE (MDR) GENES IN HEMATOLOGICAL MALIGNANCIES
     Cytotechnology
     
     K. Nooter e P. Sonneveld, "MULTIDRUG-RESISTANCE (MDR) GENES IN HEMATOLOGICAL MALIGNANCIES", Cytotechnology, 12(1-3), 1993, pp. 213-230